{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:54:11Z","timestamp":1790394851309,"version":"4.1.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T00:00:00Z","timestamp":1549238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006314","name":"Biogen Idec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006314","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s40273-019-00769-6","type":"journal-article","created":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T02:18:52Z","timestamp":1549246732000},"page":"845-865","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2840-6996","authenticated-orcid":false,"given":"Santiago","family":"Zuluaga-Sanchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Teynor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6428-0505","authenticated-orcid":false,"given":"Christopher","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lundqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Ekelund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7804-4810","authenticated-orcid":false,"given":"Annabelle","family":"Forsmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0304-1951","authenticated-orcid":false,"given":"Adrian D.","family":"Vickers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7597-6556","authenticated-orcid":false,"given":"Andrew","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,4]]},"reference":[{"key":"769_CR1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.pcl.2015.03.010","volume":"62","author":"BT Darras","year":"2015","unstructured":"Darras BT. Spinal muscular atrophies. Pediatr Clin N Am. 2015;62:743\u201366.","journal-title":"Pediatr Clin N Am."},{"key":"769_CR2","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1177\/0883073807305788","volume":"22","author":"CH Wang","year":"2007","unstructured":"Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007;22:1027\u201349.","journal-title":"J Child Neurol."},{"key":"769_CR3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.24497","volume":"51","author":"WD Arnold","year":"2015","unstructured":"Arnold WD, Kassar D, Kissel JT. Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve. 2015;51:157\u201367.","journal-title":"Muscle Nerve."},{"key":"769_CR4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S1474-4422(12)70061-3","volume":"11","author":"E Mercuri","year":"2012","unstructured":"Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol. 2012;11:443\u201352.","journal-title":"Lancet Neurol."},{"key":"769_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jpeds.2012.05.067","volume":"162","author":"MA Farrar","year":"2013","unstructured":"Farrar MA, Vucic S, Johnston HM, du Sart D, Kiernan MC. Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy. J Pediatr. 2013;162:155\u20139.","journal-title":"J Pediatr."},{"key":"769_CR6","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.nmd.2015.04.009","volume":"25","author":"R Finkel","year":"2015","unstructured":"Finkel R, Bertini E, Muntoni F, Mercuri E. 209th ENMC international workshop: outcome measures and clinical trial readiness in spinal muscular atrophy, 7\u20139 November 2014, Heemskerk, the Netherlands. Neuromuscul Disord. 2015;25:593\u2013602.","journal-title":"Neuromuscul Disord."},{"key":"769_CR7","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1001\/archneur.1995.00540290108025","volume":"52","author":"K Zerres","year":"1995","unstructured":"Zerres K, Rudnik-Schoneborn S. Natural history in proximal spinal muscular atrophy: clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995;52:518\u201323.","journal-title":"Arch Neurol."},{"issue":"3","key":"769_CR8","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1159\/000052118","volume":"45","author":"S Rudnik-Schoneborn","year":"2001","unstructured":"Rudnik-Schoneborn S, Hausmanowa-Petrusewicz I, Borkowska J, Zerres K. The predictive value of achieved motor milestones assessed in 441 patients with infantile spinal muscular atrophy types II and III. Eur Neurol. 2001;45(3):174\u201381.","journal-title":"Eur Neurol."},{"key":"769_CR9","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nrneurol.2015.77","volume":"11","author":"I Faravelli","year":"2015","unstructured":"Faravelli I, Nizzardo M, Comi GP, Corti S. Spinal muscular atrophy: recent therapeutic advances for an old challenge. Nat Rev Neurol. 2015;11:351\u20139.","journal-title":"Nat Rev Neurol."},{"issue":"5","key":"769_CR10","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/j.1651-2227.2008.01201.x","volume":"98","author":"E Arkblad","year":"2009","unstructured":"Arkblad E, Tulinius M, Kroksmark AK, Henricsson M, Darin N. A population-based study of genotypic and phenotypic variability in children with spinal muscular atrophy. Acta Paediatr. 2009;98(5):865\u201372.","journal-title":"Acta Paediatr."},{"issue":"3","key":"769_CR11","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000275492","volume":"34","author":"M Jedrzejowska","year":"2010","unstructured":"Jedrzejowska M, Milewski M, Zimowski J, Zagozdzon P, Kostera-Pruszczyk A, Borkowska J, et al. Incidence of spinal muscular atrophy in Poland: more frequent than predicted? Neuroepidemiology. 2010;34(3):152\u20137.","journal-title":"Neuroepidemiology."},{"issue":"3","key":"769_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/GIM.0b013e3181c5e713","volume":"12","author":"TW Prior","year":"2010","unstructured":"Prior TW. Perspectives and diagnostic considerations in spinal muscular atrophy. Genet Med. 2010;12(3):145\u201352.","journal-title":"Genet Med."},{"issue":"1","key":"769_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ejhg.2011.134","volume":"20","author":"EA Sugarman","year":"2012","unstructured":"Sugarman EA, Nagan N, Zhu H, Akmaev VR, Zhou Z, Rohlfs EM, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of > 72,400 specimens. Eur J Hum Genet. 2012;20(1):27\u201332.","journal-title":"Eur J Hum Genet."},{"issue":"12","key":"769_CR14","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/sj.ejhg.5201288","volume":"12","author":"S Ogino","year":"2004","unstructured":"Ogino S, Wilson RB, Gold B. New insights on the evolution of the SMN1 and SMN2 region: simulation and meta-analysis for allele and haplotype frequency calculations. Eur J Hum Genet. 2004;12(12):1015\u201323.","journal-title":"Eur J Hum Genet."},{"issue":"Pt 11","key":"769_CR15","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1093\/brain\/awp236","volume":"132","author":"FL Norwood","year":"2009","unstructured":"Norwood FL, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain. 2009;132(Pt 11):3175\u201386.","journal-title":"Brain."},{"key":"769_CR16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. Diagnosis and management of spinal muscular atrophy. Part 1. Recommendations for diagnosis, rehabilitation, orthopaedic and nutritional care. Neuromuscul Disord. 2018;28:103\u201315.","journal-title":"Neuromuscul Disord."},{"key":"769_CR17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","volume":"28","author":"RS Finkel","year":"2018","unstructured":"Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ, et al. Diagnosis and management of spinal muscular atrophy. Part 2. Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28:197\u2013207.","journal-title":"Neuromuscul Disord."},{"key":"769_CR18","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.neurol.2012.07.020","volume":"168","author":"JM Cuisset","year":"2012","unstructured":"Cuisset JM, Estournet B. Recommendations for the diagnosis and management of typical childhood spinal muscular atrophy. Rev Neurol (Paris). 2012;168:902\u20139.","journal-title":"Rev Neurol (Paris)."},{"key":"769_CR19","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.nmd.2016.10.002","volume":"26","author":"R Sanctis De","year":"2016","unstructured":"De Sanctis R, Coratti G, Pasternak A, Montes J, Pane M, Mazzone ES, et al. Developmental milestones in type I spinal muscular atrophy. Neuromuscul Disord. 2016;26:754\u20139.","journal-title":"Neuromuscul Disord."},{"issue":"11","key":"769_CR20","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1177\/0883073813503988","volume":"29","author":"RH Davis","year":"2014","unstructured":"Davis RH, Godshall BJ, Seffrood E, Marcus M, LaSalle BA, Wong B, et al. Nutritional practices at a glance: spinal muscular atrophy type I nutrition survey findings. J Child Neurol. 2014;29(11):1467\u201372.","journal-title":"J Child Neurol."},{"key":"769_CR21","first-page":"113","volume":"6","author":"G Haaker","year":"2013","unstructured":"Haaker G, Fujak A. Proximal spinal muscular atrophy: current orthopedic perspective. Appl Clin Genet. 2013;6:113\u201320.","journal-title":"Appl Clin Genet."},{"key":"769_CR22","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723\u201332.","journal-title":"N Engl J Med."},{"key":"769_CR23","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2017;388:3017\u201326.","journal-title":"Lancet."},{"key":"769_CR24","unstructured":"ClinicalTrials.gov. A study to assess the efficacy, safety and pharmacokinetics of nusinersen (ISIS 396443) in infants with spinal muscular atrophy (SMA). 2017. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01839656?term=A+Study+to+Assess+the+Efficacy%2C+Safety+and+Pharmacokinetics+of+Nusinersen+%28ISIS+396443%29+in+Infants+With+Spinal+Muscular+Atrophy+%28SMA%29.&rank=1 . Accessed 17 Nov 2017."},{"key":"769_CR25","unstructured":"ClinicalTrials.gov. A study to assess the safety and tolerability of nusinersen (ISIS 396443) in participants with spinal muscular atrophy (SMA) (EMBRACE). 2017. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02462759 . Accessed 17 Nov 2017."},{"key":"769_CR26","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378:625\u201335.","journal-title":"N Engl J Med."},{"key":"769_CR27","unstructured":"ClinicalTrials.gov. An open-label safety, tolerability and dose-range finding study of multiple doses of nusinersen (ISIS 396443) in participants with spinal muscular atrophy. 2017. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01703988?term=NCT01703988&rank=1 . Accessed 17 Nov 2017."},{"key":"769_CR28","unstructured":"ClinicalTrials.gov. An open-label safety and tolerability study of nusinersen (ISIS 396443) in participants with spinal muscular atrophy (SMA) who previously participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246). 2017. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02052791?term=NCT02052791&rank=1 . Accessed 17 Nov 2017."},{"key":"769_CR29","unstructured":"ClinicalTrials.gov. An open-label safety, tolerability, and dose-range finding study of nusinersen (ISIS 396443) in participants with spinal muscular atrophy (SMA) (SMNRx). 2017. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01494701?term=NCT01494701&rank=1 . Accessed 17 Nov 2017."},{"key":"769_CR30","unstructured":"ClinicalTrials.gov. An open-label safety and tolerability study of nusinersen (ISIS 396443) in participants with spinal muscular atrophy who previously participated in ISIS 396443-CS1 (NCT01494701). 2017. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01780246?term=NCT01780246&rank=1 . Accessed 17 Nov 2017."},{"key":"769_CR31","unstructured":"ClinicalTrials.gov. A study of multiple doses of nusinersen (ISIS 396443) delivered to infants with genetically diagnosed and presymptomatic spinal muscular atrophy (NURTURE). 2017. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02386553 . Accessed 17 Nov 2017."},{"key":"769_CR32","unstructured":"ClinicalTrials.gov. A study for participants with spinal muscular atrophy (SMA) who previously participated in nusinersen (ISIS 396443) investigational studies. (SHINE). 2017. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02594124 . Accessed 17 Nov 2017."},{"key":"769_CR33","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0022-3476(99)70016-8","volume":"135","author":"L Haataja","year":"1999","unstructured":"Haataja L, Mercuri E, Regev R, Cowan F, Rutherford M, Dubowitz V, et al. Optimality score for the neurologic examination of the infant at 12 and 18 months of age. J Pediatr. 1999;135:153\u201361.","journal-title":"J Pediatr."},{"key":"769_CR34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","volume":"20","author":"AM Glanzman","year":"2010","unstructured":"Glanzman AM, Mazzone E, Main M, Pelliccioni M, Wood J, Swoboda KJ, et al. The children\u2019s hospital of philadelphia infant test of neuromuscular disorders (CHOP INTEND): test development and reliability. Neuromuscul Disord. 2010;20:155\u201361.","journal-title":"Neuromuscul Disord."},{"key":"769_CR35","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","volume":"17","author":"JM O\u2019Hagen","year":"2007","unstructured":"O\u2019Hagen JM, Glanzman AM, McDermott MP, et al. An expanded version of the Hammersmith functional motor scale for SMA II and III patients. Neuromuscul Disord. 2007;17:693\u20137.","journal-title":"Neuromuscul Disord."},{"key":"769_CR36","doi-asserted-by":"publisher","first-page":"e12140","DOI":"10.1371\/journal.pone.0012140","volume":"5","author":"KJ Swoboda","year":"2010","unstructured":"Swoboda KJ, Scott CB, Crawford TO, Simard LR, Reyna SP, Krosschell KJ, et al. SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. PLoS One. 2010;5:e12140.","journal-title":"PLoS One."},{"key":"769_CR37","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1651-2227.2006.tb02379.x","volume":"450","author":"WHO Multicentre Growth Reference Study Group","year":"2006","unstructured":"WHO Multicentre Growth Reference Study Group. WHO Motor Development Study: windows of achievement for six gross motor development milestones. Acta Paediatr Suppl. 2006;450:86\u201395.","journal-title":"Acta Paediatr Suppl."},{"key":"769_CR38","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/mus.25430","volume":"55","author":"ES Mazzone","year":"2017","unstructured":"Mazzone ES, Mayhew A, Montes J, Ramsey D, Fanelli L, Young SD, et al. Revised upper limb module for spinal muscular atrophy: development of a new module. Muscle Nerve. 2017;55:869\u201374.","journal-title":"Muscle Nerve."},{"key":"769_CR39","unstructured":"US Food and Drug Administration. FDA news release: FDA approves first drug for spinal muscular atrophy. 2016. https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm534611.htm . Accessed 17 Nov 2017."},{"key":"769_CR40","unstructured":"European Medicines Agency. Spinraza (nusinersen). 2017. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/004312\/human_med_002119.jsp&mid=WC0b01ac058001d124 . Accessed 17 Nov 2017."},{"issue":"5","key":"769_CR41","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jval.2018.02.008","volume":"21","author":"I Pearson","year":"2018","unstructured":"Pearson I, Rothwell B, Olaye A, Knight C. Economic modeling considerations for rare diseases. Value Health. 2018;21(5):515\u201324.","journal-title":"Value Health."},{"key":"769_CR42","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","volume":"83","author":"RS Finkel","year":"2014","unstructured":"Finkel RS, McDermott MP, Kaufmann P, Darras BT, Chung WK, Sproule DM, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83:810\u20137.","journal-title":"Neurology."},{"key":"769_CR43","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.nmd.2015.10.006","volume":"26","author":"E Mercuri","year":"2016","unstructured":"Mercuri E, Finkel R, Montes J, Mazzone E, Sormani MP, Main M, et al. Patterns of disease progression in type 2 and 3 SMA: implications for clinical trials. Neuromuscul Disord. 2016;26:126\u201331.","journal-title":"Neuromuscul Disord."},{"issue":"1","key":"769_CR44","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12883-017-0853-y","volume":"17","author":"S McGraw","year":"2017","unstructured":"McGraw S, Qian Y, Henne J, Jarecki J, Hobby K, Yeh WS. A qualitative study of perceptions of meaningful change in spinal muscular atrophy. BMC Neurol. 2017;17(1):68.","journal-title":"BMC Neurol."},{"issue":"1","key":"769_CR45","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12883-017-0790-9","volume":"17","author":"MC Pera","year":"2017","unstructured":"Pera MC, Coratti G, Forcina N, Mazzone ES, Scoto M, Montes J, et al. Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy. BMC Neurol. 2017;17(1):39.","journal-title":"BMC Neurol."},{"key":"769_CR46","unstructured":"Pharmaceutical Benefits Board. General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2). 2003. https:\/\/www.tlv.se\/in-english\/medicines\/apply-for-reimbursement.html . Accessed 21 Nov 2017."},{"key":"769_CR47","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0022-510X(96)00284-5","volume":"146","author":"K Zerres","year":"1997","unstructured":"Zerres K, Rudnik-Schoneborn S, Forrest E, Lusakowska A, Borkowska J, Hausmanowa-Petrusewicz I. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci. 1997;146:67\u201372.","journal-title":"J Neurol Sci."},{"key":"769_CR48","unstructured":"Spinal Muscular Atrophy Support UK. SMA drug pipeline. 2018. http:\/\/www.smasupportuk.org.uk\/drug-pipeline . Accessed 15 Aug 2018."},{"key":"769_CR49","unstructured":"Latimer N. NICE DSU technical support document 14. Survival analysis for economic evaluations alongside clinical trials: extrapolation with patient level data. 2013. http:\/\/www.nicedsu.org.uk\/NICE%20DSU%20TSD%20Survival%20analysis.updated%20March%202013.v2.pdf . Accessed 5 May 2017."},{"key":"769_CR50","doi-asserted-by":"publisher","first-page":"e1509","DOI":"10.1542\/peds.2012-2278","volume":"131","author":"C Gregoretti","year":"2013","unstructured":"Gregoretti C, Ottonello G, Chiarini Testa MB, Mastella C, Rava L, Bignamini E, et al. Survival of patients with spinal muscular atrophy type 1. Pediatrics. 2013;131:e1509\u201314.","journal-title":"Pediatrics."},{"key":"769_CR51","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1212\/01.wnl.0000290830.40544.b9","volume":"69","author":"M Oskoui","year":"2007","unstructured":"Oskoui M, Levy G, Garland CJ, Gray JM, O\u2019Hagen J, De Vivo DC, et al. The changing natural history of spinal muscular atrophy type 1. Neurology. 2007;69:1931\u20136.","journal-title":"Neurology."},{"key":"769_CR52","unstructured":"Tandv\u00e5rds-och l\u00e4kemedelsf\u00f6rm\u00e5nsverkets f\u00f6rfattningssamling. Spinraza (nusinersen) intended for the treatment of spinal muscle atrophy of type 5q. 2017. https:\/\/www.tlv.se\/download\/18.73f5568815f9b31688a88ff4\/1510556738560\/halsoekonomisk_bedomning171108_underlag_spinraza.pdf . Accessed 21 Feb 2018."},{"key":"769_CR53","volume-title":"Solving least squares problems","author":"CHR Lawson","year":"1974","unstructured":"Lawson CHR. Solving least squares problems. Englewood Cliffs: Prentice-Hall; 1974."},{"key":"769_CR54","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1177\/0883073811420152","volume":"27","author":"X Ge","year":"2012","unstructured":"Ge X, Bai J, Lu Y, Qu Y, Song F. The natural history of infant spinal muscular atrophy in China: a study of 237 patients. J Child Neurol. 2012;27:471\u20137.","journal-title":"J Child Neurol."},{"key":"769_CR55","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/CND.0b013e318190310f","volume":"10","author":"MM Mannaa","year":"2009","unstructured":"Mannaa MM, Kalra M, Wong B, Cohen AP, Amin RS. Survival probabilities of patients with childhood spinal muscle atrophy. J Clin Neuromuscul Dis. 2009;10:85\u20139.","journal-title":"J Clin Neuromuscul Dis."},{"key":"769_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v050.i11","volume":"50","author":"UB Mogensen","year":"2012","unstructured":"Mogensen UB, Ishwaran H, Gerds TA. evaluating random forests for survival analysis using prediction error curves. J Stat Software. 2012;50:1\u201323.","journal-title":"J Stat Software."},{"issue":"1","key":"769_CR57","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-016-0424-0","volume":"11","author":"C Klug","year":"2016","unstructured":"Klug C, Schreiber-Katz O, Thiele S, Schorling E, Zowe J, Reilich P, et al. Disease burden of spinal muscular atrophy in Germany. Orphanet J Rare Dis. 2016;11(1):58.","journal-title":"Orphanet J Rare Dis."},{"key":"769_CR58","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13023-017-0695-0","volume":"12","author":"J L\u00f3pez-Bastida","year":"2017","unstructured":"L\u00f3pez-Bastida J, Pena-Longobardo LM, Aranda-Reneo I, Tizzano E, Sefton M, Oliva-Moreno J. Social\/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain. Orphanet J Rare Dis. 2017;12:141.","journal-title":"Orphanet J Rare Dis."},{"key":"769_CR59","unstructured":"Apoteket. https:\/\/www.apoteket.se\/produkt\/spinraza-injektionsvatska-losning-12-mg-1-x-5-milliliter-injektionsflaska-534913\/ . Accessed 2 Apr 2017."},{"key":"769_CR60","unstructured":"S\u00f6dra Regionv\u00e5rdsn\u00e4mnden. Regional prices and refund rates for the Southern health care region, 2018. 2018. http:\/\/sodrasjukvardsregionen.se\/avtal-priser\/regionala-priser-och-ersattningar\/ . Accessed 21 Nov 2018."},{"key":"769_CR61","unstructured":"Tulinius M, Bruno C, Deconinck N, Schara U, Finkel RS, Bhan I, et al. Nusinersen decreases the incidence and length of hospitalisations in infants with spinal muscular atrophy: results from the ENDEAR study. Poster presented at SMA Europe\u2019s International Scientific Congress on SMA; Krak\u00f3w; 25\u201327 Jan 2018."},{"key":"769_CR62","doi-asserted-by":"crossref","unstructured":"Lloyd AJ, Gallop K, Thompson R, Vaidya S, Teynor M. Estimation of the health-related quality of life benefits of treatment for spinal muscular atrophy (SMA). Poster presented at the ISPOR 20th Annual European Congress; Glasgow; 4\u20136 Nov 2017.","DOI":"10.1016\/j.jval.2017.08.911"},{"key":"769_CR63","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40273-014-0153-y","volume":"32","author":"KA Khan","year":"2014","unstructured":"Khan KA, Petrou S, Rivero-Arias O, Walters J, Boyle SE. Mapping EQ-5D utility scores from the PedsQL\u2122 generic core scales. Pharmacoeconomics. 2014;32:693\u2013706.","journal-title":"Pharmacoeconomics."},{"key":"769_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1524-4733.2005.08101.x","volume":"8","author":"A Briggs","year":"2005","unstructured":"Briggs A. Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value Health. 2005;8:1\u20132.","journal-title":"Value Health."},{"key":"769_CR65","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jval.2012.04.012","volume":"15","author":"DM Eddy","year":"2012","unstructured":"Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB. Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force-7. Value Health. 2012;15:843\u201350.","journal-title":"Value Health."},{"key":"769_CR66","unstructured":"National Institute for Health and Care Excellence. Single technology appraisal: nusinersen for treating spinal muscular atrophy [ID1069]. Committee papers. Manchester: National Institute for Health and Care Excellence; 2018. https:\/\/www.nice.org.uk\/guidance\/gid-ta10281\/documents\/committee-papers ."},{"key":"769_CR67","unstructured":"Canadian Agency for Drugs and Technologies in Health. Pharmacoeconomic review report: nusinersen for treatment of patients with 5q SMA. Canadian Agency for Drugs and Technologies in Health; 2018. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK534118\/pdf\/Bookshelf_NBK534118.pdf ."},{"key":"769_CR68","unstructured":"National Centre for Pharmacoeconomics. Cost-effectiveness of nusinersen (Spinraza) for the treatment of 5q spinal muscular atrophy (SMA). National Centre for Pharmacoeconomics; 2017. http:\/\/www.ncpe.ie\/wp-content\/uploads\/2017\/08\/Summary-Nusinersen.pdf ."},{"key":"769_CR69","unstructured":"Scottish Medicines Consortium. Nusinersen for the treatment of 5q spinal muscular atrophy (SMA). Glasgow: Scottish Medicines Consortium (SMC); 2018. https:\/\/www.scottishmedicines.org.uk\/media\/3415\/nusinersen-spinraza-final-april-2018-for-website.pdf ."},{"key":"769_CR70","unstructured":"Zorginstituut Nederland. Package advice nusinersen (Spinraza\u00ae) for the treatment of spinal muscular atrophy (SMA). 2018. https:\/\/www.zorginstituutnederland.nl\/publicaties\/adviezen\/2018\/02\/07\/pakketadvies-nusinersen-spinraza-voor-de-behandeling-van-spinale-musculaire-atrofie-sma . Accessed 15 Jun 2018."},{"key":"769_CR71","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13023-015-0305-y","volume":"10","author":"Y Schuller","year":"2015","unstructured":"Schuller Y, Hollak CE, Biegstraaten M. The quality of economic evaluations of ultra-orphan drugs in Europe: a systematic review. Orphanet J Rare Dis. 2015;10:92.","journal-title":"Orphanet J Rare Dis."},{"key":"769_CR72","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40273-016-0461-5","volume":"35","author":"E Landfeldt","year":"2017","unstructured":"Landfeldt E, Alfredsson L, Straub V, Lochm\u00fcller H, Bushby K, Lindgren P. Economic evaluation in Duchenne muscular dystrophy: model frameworks for cost-effectiveness analysis. Pharmacoeconomics. 2017;35:249\u201358.","journal-title":"Pharmacoeconomics."},{"issue":"11","key":"769_CR73","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40273-015-0307-6","volume":"33","author":"M Svensson","year":"2015","unstructured":"Svensson M, Nilsson FO, Arnberg K. Reimbursement decisions for pharmaceuticals in Sweden: the impact of disease severity and cost effectiveness. Pharmacoeconomics. 2015;33(11):1229\u201336.","journal-title":"Pharmacoeconomics."},{"key":"769_CR74","unstructured":"Tandv\u00e5rds-och l\u00e4kemedelsf\u00f6rm\u00e5nsverkets. Underlag f\u00f6r beslut om subvention: Cerezyme och Vpriv. https:\/\/www.tlv.se\/download\/18.467926b615d084471ac33d95\/1510316366212\/Bes161219_underlag_for_beslut_cerezyme_vpriv.pdf . Accessed 21 Feb 2018."},{"key":"769_CR75","unstructured":"Teynor M, Thompson R, Lundqvist T, Ekelund M, Zuluaga-Sancez S, Knight C. Benchmarking utility estimates in rare diseases may guide the selection of data inputs in health economic modeling. Poster presented at the 9th European Conference on Rare Diseases and Orphan Products; Vienna; 10\u201312 May 2018."},{"key":"769_CR76","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1023\/A:1013171831202","volume":"10","author":"K Burstr\u00f6m","year":"2001","unstructured":"Burstr\u00f6m K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res. 2001;10:621\u201335.","journal-title":"Qual Life Res."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-019-00769-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-019-00769-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-019-00769-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T14:24:58Z","timestamp":1720967098000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-019-00769-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,4]]},"references-count":76,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["769"],"URL":"https:\/\/doi.org\/10.1007\/s40273-019-00769-6","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,4]]},"assertion":[{"value":"4 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Open access fees were funded by Biogen Inc. This study was funded by Biogen Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Santiago Zuluaga Sanchez, Christopher Knight and Adrian D. Vickers are full-time employees of RTI Health Solutions, which received funding from Biogen Inc. to conduct this study. The contract between RTI Health Solutions and the sponsor includes independent publication rights. RTI Health Solutions conducts work for the government, public and private organisations, including pharmaceutical companies. Robin Thompson, Thomas Lundqvist and Mats Ekelund are employees of Biogen Inc. Megan Teynor is a former employee of Biogen Inc. Annabelle Forsmark is a full-time employee of Nordic Health Economics AB, which received funding from Biogen Inc. for contributing to this study. Nordic Health Economics AB conducts work involving health economics and outcomes research for the government, public and private sectors. Andrew Lloyd is a Director of Acaster Lloyd Consulting Ltd, which received funding from Biogen Inc. for work that supported the modelling exercise.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The model generated during the current study is not publicly available because it includes patient-level data from the ENDEAR and CHERISH clinical trials that could be deanonymized.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent procedures were not applicable to this study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}}]}}